MET and hepatocellular carcinoma: Indeed, HER2 blockade with afatinib, lapatinib, or trastuzumab did not demonstrate any antitumor efficacy in two METN375S-positive patient-derived xenografts (PDX) of hepatocellular carcinoma (HCC) (Supplementary Fig. 9D–G), in which phosphorylations of MET and HER2 were not prominent in the tumors (Supplementary Fig. 9H, I).